PTN vs. CPIX, STSA, NLTX, KALA, CRBP, LPCN, LUMO, HBPCF, MBRX, and IGXT
Should you be buying Palatin Technologies stock or one of its competitors? The main competitors of Palatin Technologies include Cumberland Pharmaceuticals (CPIX), Satsuma Pharmaceuticals (STSA), Neoleukin Therapeutics (NLTX), Kala Pharmaceuticals (KALA), Corbus Pharmaceuticals (CRBP), Lipocine (LPCN), Lumos Pharma (LUMO), Helix BioPharma (HBPCF), Moleculin Biotech (MBRX), and IntelGenx Technologies (IGXT). These companies are all part of the "pharmaceutical preparations" industry.
Palatin Technologies vs.
Palatin Technologies (NYSEAMERICAN:PTN) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
Palatin Technologies currently has a consensus target price of $60.00, suggesting a potential upside of 1,835.48%. Given Palatin Technologies' higher possible upside, equities analysts plainly believe Palatin Technologies is more favorable than Cumberland Pharmaceuticals.
9.0% of Palatin Technologies shares are held by institutional investors. Comparatively, 16.7% of Cumberland Pharmaceuticals shares are held by institutional investors. 9.9% of Palatin Technologies shares are held by insiders. Comparatively, 43.6% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Palatin Technologies has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.
In the previous week, Cumberland Pharmaceuticals had 10 more articles in the media than Palatin Technologies. MarketBeat recorded 10 mentions for Cumberland Pharmaceuticals and 0 mentions for Palatin Technologies. Palatin Technologies' average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.27 indicating that Palatin Technologies is being referred to more favorably in the media.
Cumberland Pharmaceuticals has a net margin of -13.26% compared to Palatin Technologies' net margin of -1,713.72%. Cumberland Pharmaceuticals' return on equity of 1.48% beat Palatin Technologies' return on equity.
Cumberland Pharmaceuticals has higher revenue and earnings than Palatin Technologies. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Palatin Technologies, indicating that it is currently the more affordable of the two stocks.
Palatin Technologies received 257 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 73.15% of users gave Palatin Technologies an outperform vote while only 51.80% of users gave Cumberland Pharmaceuticals an outperform vote.
Summary
Cumberland Pharmaceuticals beats Palatin Technologies on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSEAMERICAN and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palatin Technologies Competitors List
